Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
MWN-AI** Summary
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company, has announced that its abstract highlighting long-term neurological benefits of ALXN1840 (tiomolybdate choline) in patients with Wilson disease has been accepted for both oral and poster presentations at the 150th American Neurological Association (ANA) Annual Meeting. This significant conference is set to take place from September 13-16, 2025, in Baltimore, Maryland.
The abstract, titled “Long-term sustained improvement of neurological symptoms in Wilson disease patients on tiomolybdate choline,” has been recognized by the ANA as an “Abstract of Distinction,” a prestigious acknowledgment that ensures it receives special recognition during the event and inclusion in the abstract compendium published in the Annals of Neurology.
Details of the presentations include a poster session scheduled for Sunday, September 14, from 5:30-7:00 PM EST, and an oral session on Monday, September 15, from 3:45-5:15 PM EST. Dr. Matthew Lorincz, a distinguished professor of neurology at the University of Michigan and co-director of the Wilson Disease Center of Excellence, will be presenting the findings.
Monopar is actively advancing its late-stage candidate, ALXN1840, targeted at treating Wilson disease, alongside its pipeline of radiopharmaceutical projects designed for imaging and treating advanced cancers. The company emphasizes its commitment to developing innovative treatments for unmet medical needs.
Investors and interested parties can access the presentations online through Monopar's website on the specified dates. However, the company warns that forward-looking statements about future developments carry inherent risks, reflecting the uncertainties involved in the regulatory and market landscapes related to their drug candidates.
MWN-AI** Analysis
Monopar Therapeutics Inc. (Nasdaq: MNPR) has recently garnered attention due to its acceptance of an abstract with distinction for oral and poster presentations at the upcoming American Neurological Association Annual Meeting. Their research focuses on ALXN1840 (tiomolybdate choline), targeting Wilson disease, which represents a niche market with significant unmet medical needs. The choice of Monopar as a presenter underscores the potential impact of their findings, suggesting that the drug may demonstrate long-term neurological benefits, which could pave the way for clinical advancement and market approval.
Investors should observe how these presentations resonate within the broader medical community and among regulators, particularly given that an Abstract of Distinction can enhance visibility and credibility. The timing of the presentations, set for September 14 and 15, will be crucial; positive reception may lead to increased investor confidence and a potential upward movement in stock prices.
However, while the prospect of ALXN1840 entering the market is promising, it's important to acknowledge the inherent risks outlined in Monopar’s disclosures. These include uncertainties around regulatory approvals, market competition, and the financial viability of continuing their clinical trials and precommercial efforts. As a clinical-stage biopharmaceutical company, Monopar's ability to secure funding to support ongoing and future projects is vital to its survival and growth.
For investors considering entering or expanding their position in Monopar, the upcoming presentations offer not just an opportunity to assess potential stock growth but also a chance to gauge the viability of its clinical pipeline amidst a competitive landscape. It may be prudent to adopt a wait-and-see approach after the conference, allowing market reactions to crystallize before making any significant investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WILMETTE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that its abstract on the long-term neurological benefits of ALXN1840 (tiomolybdate choline) in Wilson disease patients has been selected for both oral and poster presentations at the 150 th American Neurological Association (ANA) Annual Meeting, to be held September 13-16, 2025, in Baltimore, Maryland.
The abstract, titled “ Long-term sustained improvement of neurological symptoms in Wilson disease patients on tiomolybdate choline ,” has been designated by the ANA as an Abstract of Distinction – an honor awarded to a select group of submissions that will receive special recognition during the conference and in the Annals of Neurology abstract compendium.
Presentation Details:
- Title: Long-term sustained improvement of neurological symptoms in Wilson disease patients on tiomolybdate choline
- Session: Movement Disorders
- Poster number: S247
- Poster session: Sunday, September 14, 5:30-7:00 pm EST
- Oral session: Monday, September 15, 3:45-5:15 pm EST
- Presenter: Matthew Lorincz, M.D., Ph.D., University of Michigan, Professor of Neurology and Co-Director of the Wilson Disease Center of Excellence
The poster and oral presentations will be available online at www.monopartx.com on September 14, 2025, and September 15, 2025, respectively.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage ALXN1840 for Wilson disease, and radiopharmaceutical programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: www.monopartx.com .
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements involve risks and uncertainties including, but not limited to: uncertainties related to the regulatory process that Monopar intends to initiate related to ALXN1840 and the outcome thereof; the rate of market acceptance and competitiveness in terms of pricing, efficacy and safety, of any products for which Monopar receives marketing approval, and Monopar’s ability to competitively market any such products as compared to larger pharmaceutical firms; Monopar’s ability to raise sufficient funds in order for the Company to support continued preclinical, clinical, regulatory, precommercial and commercial development of its programs and to make contractual milestone payments, as well as its ability to further raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, the approval processes and, if applicable, commercialization; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Quan Vu
Chief Financial Officer
vu@monopartx.com
Follow Monopar on social media for updates:
X: @MonoparTx? LinkedIn: Monopar Therapeutics
FAQ**
How does Monopar Therapeutics Inc. MNPR plan to address potential regulatory challenges for ALXN1840 in Wilson disease after the positive presentation at the ANA Annual Meeting?
What are the primary competitive advantages that Monopar Therapeutics Inc. MNPR believes ALXN1840 has over existing treatments for Wilson disease, especially regarding pricing and efficacy?
Can Monopar Therapeutics Inc. MNPR provide specific details on the funding strategies it intends to utilize to support the clinical development of both its Wilson disease and advanced cancer treatment programs?
Considering the Abstract of Distinction designation at the ANA meeting, what impact does Monopar Therapeutics Inc. MNPR anticipate this recognition will have on investor interest and market acceptance of ALXN1840?
**MWN-AI FAQ is based on asking OpenAI questions about Monopar Therapeutics Inc. (NASDAQ: MNPR).
NASDAQ: MNPR
MNPR Trading
-2.45% G/L:
$57.19 Last:
76,747 Volume:
$57.76 Open:
